PriceTargets.com logo

Thermo Fisher Scientific - TMO Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $602.35
  • Forecasted Upside: 4.80%
  • Number of Analysts: 24
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 19 Buy Ratings
  • 1 Strong Buy Ratings
$574.76 As of 12/4/2025 04:59 PM ET
▼ -5.686 (-0.98%)

This chart shows the closing price for TMO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Thermo Fisher Scientific Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TMO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TMO

Analyst Price Target is $602.35
▲ +4.80% Upside Potential
This price target is based on 24 analysts offering 12 month price targets for Thermo Fisher Scientific in the last 3 months. The average price target is $602.35, with a high forecast of $670.00 and a low forecast of $510.00. The average price target represents a 4.80% upside from the last price of $574.76.

This chart shows the closing price for TMO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 24 polled investment analysts is to moderate buy stock in Thermo Fisher Scientific. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 14 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 17 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 18 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 16 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 16 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 19 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 19 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 19 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/2/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$656.00 ➝ $670.00
12/1/2025Hsbc Global ResUpgradeHold ➝ Strong-Buy
10/29/2025ArgusBoost TargetBuy ➝ Buy$580.00 ➝ $610.00
10/28/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$560.00 ➝ $656.00
10/23/2025CowenReiterated RatingBuy ➝ Buy
10/23/2025UBS GroupBoost TargetNeutral ➝ Neutral$500.00 ➝ $590.00
10/23/2025Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Buy
10/23/2025TD CowenBoost TargetBuy ➝ Buy$612.00 ➝ $654.00
10/23/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$565.00 ➝ $635.00
10/23/2025BarclaysBoost TargetOverweight ➝ Overweight$585.00 ➝ $625.00
10/23/2025CitigroupBoost TargetNeutral ➝ Neutral$500.00 ➝ $580.00
10/22/2025Leerink PartnersBoost TargetOutperform ➝ Outperform$545.00 ➝ $580.00
10/14/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
10/9/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$600.00 ➝ $650.00
10/8/2025Redburn PartnersSet Target$580.00
10/7/2025Evercore ISIBoost TargetOutperform ➝ Outperform$525.00 ➝ $590.00
10/2/2025BarclaysBoost TargetOverweight ➝ Overweight$550.00 ➝ $585.00
9/27/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
9/11/2025BarclaysUpgradeEqual Weight ➝ Overweight$490.00 ➝ $550.00
9/2/2025Royal Bank Of CanadaSet TargetOutperform ➝ Outperform$561.00
8/18/2025William BlairInitiated CoverageOutperform
7/24/2025Hsbc Global ResDowngradeStrong-Buy ➝ Hold
7/24/2025UBS GroupBoost TargetNeutral ➝ Neutral$460.00 ➝ $500.00
7/24/2025Raymond James FinancialReiterated RatingOutperform ➝ Outperform$525.00 ➝ $535.00
7/24/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$570.00 ➝ $565.00
7/24/2025HSBCReiterated RatingBuy ➝ Hold$510.00
7/24/2025BarclaysBoost TargetEqual Weight ➝ Equal Weight$450.00 ➝ $490.00
7/24/2025Robert W. BairdBoost TargetOutperform ➝ Outperform$553.00 ➝ $567.00
7/18/2025Robert W. BairdLower TargetOutperform ➝ Outperform$573.00 ➝ $553.00
7/11/2025ScotiabankUpgradeSector Perform ➝ Sector Outperform$590.00
7/8/2025UBS GroupDowngradeBuy ➝ Neutral$500.00 ➝ $460.00
7/8/2025Evercore ISILower TargetOutperform ➝ Outperform$500.00 ➝ $480.00
6/24/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$475.00 ➝ $450.00
4/29/2025ArgusLower TargetBuy ➝ Buy$620.00 ➝ $470.00
4/25/2025ScotiabankLower TargetSector Perform ➝ Sector Perform$650.00 ➝ $605.00
4/24/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$651.00 ➝ $637.00
4/24/2025UBS GroupLower TargetBuy ➝ Buy$715.00 ➝ $500.00
4/24/2025Stifel NicolausLower TargetBuy ➝ Buy$665.00 ➝ $620.00
4/24/2025Evercore ISILower TargetOutperform ➝ Outperform$585.00 ➝ $500.00
4/24/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$580.00 ➝ $570.00
4/24/2025Robert W. BairdLower TargetOutperform ➝ Outperform$603.00 ➝ $573.00
4/23/2025The Goldman Sachs GroupSet TargetBuy ➝ Buy$610.00
4/17/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$680.00 ➝ $580.00
4/10/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$620.00 ➝ $475.00
3/4/2025CitigroupLower TargetNeutral ➝ Neutral$650.00 ➝ $570.00
2/3/2025ScotiabankBoost TargetSector Perform ➝ Sector Perform$605.00 ➝ $650.00
2/3/2025Raymond James FinancialReiterated RatingOutperform ➝ Outperform$650.00 ➝ $667.00
1/31/2025Royal Bank Of CanadaSet Target$693.00
1/31/2025CitigroupBoost TargetNeutral ➝ Neutral$600.00 ➝ $650.00
1/31/2025UBS GroupBoost TargetBuy ➝ Buy$700.00 ➝ $715.00
1/31/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$660.00 ➝ $680.00
1/31/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$647.00 ➝ $678.00
1/13/2025Morgan StanleyLower TargetOverweight ➝ Overweight$670.00 ➝ $647.00
1/10/2025Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$630.00
12/23/2024ScotiabankInitiated CoverageSector Perform$605.00
12/13/2024Bank of AmericaLower TargetBuy ➝ Buy$675.00 ➝ $660.00
10/24/2024Sanford C. BernsteinLower TargetMarket Perform ➝ Market Perform$625.00 ➝ $620.00
10/24/2024Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$767.00 ➝ $718.00
10/24/2024Stifel NicolausLower TargetBuy ➝ Buy$680.00 ➝ $665.00
10/24/2024Evercore ISILower TargetOutperform ➝ Outperform$630.00 ➝ $620.00
10/24/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$670.00 ➝ $660.00
10/24/2024Robert W. BairdLower TargetOutperform ➝ Outperform$632.00 ➝ $622.00
10/23/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$620.00 ➝ $610.00
10/22/2024TD CowenBoost Target$656.00 ➝ $686.00
10/22/2024Bernstein BankBoost TargetMarket Perform ➝ Market Perform$565.00 ➝ $625.00
10/15/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$600.00 ➝ $620.00
10/14/2024Redburn AtlanticInitiated CoverageBuy$680.00
10/1/2024Evercore ISIBoost TargetOutperform ➝ Outperform$605.00 ➝ $630.00
10/1/2024StephensInitiated CoverageOverweight$680.00
9/20/2024Stifel NicolausBoost TargetBuy ➝ Buy$615.00 ➝ $680.00
9/20/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$650.00 ➝ $670.00
9/20/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$655.00 ➝ $680.00
9/20/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$767.00 ➝ $767.00
9/16/2024UBS GroupUpgradeStrong-Buy
9/16/2024Bank of AmericaBoost TargetBuy ➝ Buy$600.00 ➝ $675.00
8/27/2024Wells Fargo & CompanyInitiated CoverageOverweight$670.00
7/25/2024TD CowenBoost TargetBuy ➝ Buy$648.00 ➝ $658.00
7/25/2024Raymond James FinancialBoost TargetOutperform ➝ Outperform$650.00 ➝ $660.00
7/25/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$660.00 ➝ $664.00
7/25/2024Stifel NicolausBoost TargetBuy ➝ Buy$600.00 ➝ $615.00
7/25/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$620.00 ➝ $632.00
7/2/2024Evercore ISILower TargetOutperform ➝ Outperform$615.00 ➝ $600.00
6/28/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$615.00 ➝ $600.00
6/3/2024Jefferies Financial GroupReiterated RatingHold ➝ Buy$600.00 ➝ $650.00
4/30/2024HSBCBoost TargetBuy ➝ Buy$660.00 ➝ $670.00
4/25/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$590.00 ➝ $615.00
4/25/2024Deutsche Bank AktiengesellschaftBoost TargetBuy ➝ Buy$600.00 ➝ $610.00
4/25/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$600.00 ➝ $650.00
4/25/2024Robert W. BairdLower TargetOutperform ➝ Outperform$621.00 ➝ $620.00
4/17/2024HSBCBoost TargetBuy ➝ Buy$630.00 ➝ $660.00
4/10/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$550.00 ➝ $640.00
4/4/2024Evercore ISIBoost TargetOutperform ➝ Outperform$575.00 ➝ $610.00
3/18/2024CitigroupInitiated CoverageNeutral$620.00
2/1/2024Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$592.00 ➝ $642.00
2/1/2024Raymond James FinancialBoost TargetOutperform ➝ Outperform$515.00 ➝ $605.00
1/24/2024BarclaysDowngradeOverweight ➝ Equal Weight$475.00 ➝ $555.00
1/8/2024Sanford C. BernsteinReiterated RatingOutperform ➝ Market Perform
12/18/2023HSBCInitiated CoverageBuy$610.00
12/14/2023Robert W. BairdReiterated RatingOutperform ➝ Outperform$670.00
12/13/2023Wolfe ResearchInitiated CoverageOutperform$575.00
12/11/2023CitigroupBoost TargetBuy ➝ Buy$530.00 ➝ $575.00
10/26/2023Stifel NicolausLower TargetBuy ➝ Buy$660.00 ➝ $530.00
10/26/2023Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$657.00 ➝ $579.00
10/26/2023CitigroupLower TargetBuy ➝ Buy$625.00 ➝ $530.00
10/26/2023Raymond James FinancialLower TargetOutperform ➝ Outperform$580.00 ➝ $515.00
10/26/2023KeyCorpDowngradeOverweight ➝ Sector Weight
10/25/2023Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$475.00
10/24/2023Morgan StanleyLower TargetOverweight ➝ Overweight$640.00 ➝ $600.00
10/18/2023Raymond James FinancialLower TargetOutperform ➝ Outperform$630.00 ➝ $580.00
10/17/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$670.00 ➝ $630.00
10/2/2023CitigroupReiterated RatingBuy ➝ Buy$625.00
9/29/2023BarclaysLower Target$625.00 ➝ $585.00
9/28/2023Sanford C. BernsteinInitiated CoverageOutperform$603.00
9/6/2023CitigroupInitiated CoverageBuy ➝ Buy$625.00
7/28/2023Wells Fargo & CompanyBoost TargetUnderweight$505.00 ➝ $520.00
7/28/2023Raymond James FinancialBoost TargetOutperform$595.00 ➝ $630.00
7/27/2023Royal Bank Of CanadaBoost Target$662.00 ➝ $698.00
7/27/2023JPMorgan Chase & Co.Boost Target$660.00 ➝ $670.00
7/27/2023Robert W. BairdLower TargetOutperform$664.00 ➝ $625.00
7/27/2023BarclaysBoost TargetOverweight$590.00 ➝ $625.00
7/19/2023Robert W. BairdLower TargetOutperform$670.00 ➝ $664.00
7/18/2023Raymond James FinancialInitiated CoverageOutperform$595.00
7/13/2023Credit Suisse GroupUpgradeNeutral ➝ Outperform$620.00
6/27/2023BarclaysLower Target$610.00 ➝ $590.00
5/25/2023KeyCorpLower Target$710.00 ➝ $640.00
5/25/2023JPMorgan Chase & Co.Lower Target$675.00 ➝ $660.00
4/27/2023CitigroupLower Target$700.00 ➝ $650.00
4/27/2023Morgan StanleyLower Target$670.00 ➝ $620.00
4/27/2023Robert W. BairdLower Target$693.00 ➝ $670.00
4/27/2023BarclaysLower Target$625.00 ➝ $610.00
4/4/2023Evercore ISILower TargetOutperform$615.00 ➝ $610.00
4/4/2023BarclaysLower TargetOverweight$660.00 ➝ $625.00
2/2/2023Leerink PartnersBoost TargetOutperform$620.00 ➝ $630.00
2/2/2023Morgan StanleyBoost TargetOverweight$613.00 ➝ $670.00
2/2/2023CowenBoost TargetOutperform$690.00 ➝ $711.00
2/2/2023Robert W. BairdLower Target$710.00 ➝ $693.00
2/2/2023BarclaysBoost TargetOverweight$630.00 ➝ $660.00
2/2/2023CitigroupBoost TargetBuy$650.00 ➝ $700.00
1/24/2023BarclaysBoost TargetOverweight$570.00 ➝ $630.00
1/6/2023Leerink PartnersBoost TargetOutperform$555.00 ➝ $620.00
1/3/2023Wells Fargo & CompanyLower TargetUnderweight$525.00 ➝ $505.00
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$620.00
12/6/2022Royal Bank Of CanadaInitiated CoverageOutperform$661.00
11/29/2022BarclaysLower TargetOverweight$575.00 ➝ $570.00
10/27/2022Credit Suisse GroupLower Target$620.00
10/27/2022Morgan StanleyLower TargetOverweight$678.00 ➝ $613.00
10/27/2022Robert W. BairdLower TargetOutperform$711.00 ➝ $696.00
10/27/2022CitigroupLower TargetBuy$715.00 ➝ $650.00
10/27/2022BenchmarkDowngradeBuy ➝ Hold
10/27/2022BarclaysLower TargetOverweight$595.00 ➝ $575.00
10/27/2022Leerink PartnersLower TargetOutperform$590.00 ➝ $555.00
9/12/2022BarclaysLower TargetOverweight$685.00 ➝ $595.00
8/24/2022Credit Suisse GroupInitiated CoverageNeutral$675.00
8/9/2022BarclaysBoost Target$685.00
8/1/2022BarclaysBoost TargetOverweight$630.00 ➝ $685.00
7/29/2022Morgan StanleyBoost TargetOverweight$670.00 ➝ $678.00
7/29/2022Leerink PartnersBoost TargetOutperform$630.00 ➝ $650.00
7/13/2022BarclaysLower TargetOverweight$675.00 ➝ $630.00
4/25/2022Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$605.00 ➝ $525.00
2/3/2022BTIG ResearchReiterated RatingBuy$718.00
2/3/2022Wells Fargo & CompanyLower TargetEqual Weight$700.00 ➝ $605.00
1/26/2022BarclaysInitiated CoverageOverweight ➝ Overweight$700.00
12/14/2021Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$625.00 ➝ $700.00
10/28/2021Morgan StanleyInitiated CoverageOverweight
10/28/2021Robert W. BairdBoost TargetOutperform$635.00 ➝ $657.00
10/28/2021CitigroupBoost TargetBuy$700.00 ➝ $715.00
10/28/2021Leerink PartnersBoost TargetOutperform ➝ Outperform$675.00 ➝ $685.00
10/20/2021CitigroupUpgradeNeutral ➝ Buy$620.00 ➝ $700.00
10/14/2021CowenBoost TargetOutperform$655.00 ➝ $696.00
9/23/2021The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy
9/23/2021CowenBoost TargetOutperform$560.00 ➝ $655.00
9/22/2021BenchmarkBoost TargetPositive ➝ Buy$580.00 ➝ $650.00
9/22/2021BTIG ResearchBoost TargetBuy$610.00 ➝ $700.00
9/21/2021UBS GroupBoost TargetBuy$595.00 ➝ $670.00
9/20/2021Jefferies Financial GroupInitiated CoverageHold$540.00
9/20/2021Leerink PartnersBoost TargetOutperform$600.00 ➝ $675.00
9/20/2021KeyCorpBoost TargetOverweight$555.00 ➝ $710.00
9/20/2021JPMorgan Chase & Co.Boost TargetOverweight$600.00 ➝ $700.00
9/20/2021CitigroupBoost TargetNeutral$535.00 ➝ $620.00
8/4/2021ArgusBoost TargetAverage ➝ Buy$530.00 ➝ $600.00
7/29/2021CowenBoost TargetOutperform$525.00 ➝ $560.00
7/29/2021BTIG ResearchBoost TargetBuy$590.00 ➝ $610.00
7/19/2021Leerink PartnersReiterated RatingOutperform
7/16/2021BenchmarkInitiated CoverageBuy$580.00
7/12/2021KeyCorpBoost TargetOverweight$520.00 ➝ $555.00
6/23/2021Robert W. BairdBoost TargetPositive ➝ Outperform$545.00 ➝ $550.00
6/15/2021The Goldman Sachs GroupLower TargetBuy$590.00 ➝ $530.00
5/3/2021Robert W. BairdReiterated RatingBuy
4/16/2021Evercore ISIBoost TargetOutperform$525.00 ➝ $540.00
3/29/2021UBS GroupLower TargetBuy$588.00 ➝ $560.00
3/18/2021KeyCorpUpgradeSector Weight ➝ Overweight$520.00
3/8/2021BarclaysInitiated CoverageOverweight$525.00
3/2/2021BarclaysInitiated CoverageOverweight$525.00
2/3/2021BTIG ResearchBoost TargetBuy$540.00 ➝ $590.00
2/2/2021CitigroupBoost TargetBuy$500.00 ➝ $530.00
2/2/2021Stifel NicolausBoost TargetBuy$530.00 ➝ $600.00
2/2/2021CowenBoost TargetOutperform$525.00 ➝ $585.00
2/2/2021Morgan StanleyBoost TargetOverweight$535.00 ➝ $575.00
2/2/2021UBS GroupBoost TargetPositive ➝ Buy$566.00 ➝ $588.00
2/2/2021Leerink PartnersBoost TargetOutperform$525.00 ➝ $560.00
1/12/2021Credit Suisse GroupBoost Target$556.00 ➝ $580.00
1/8/2021Credit Suisse GroupUpgradeNeutral ➝ Outperform$490.00 ➝ $556.00
12/16/2020Smith Barney CitigroupDowngradeBuy ➝ Neutral
(Data available from 12/4/2020 forward)

News Sentiment Rating

1.53 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 151 very positive mentions
  • 30 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
11/4/2025
  • 263 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 263 very positive mentions
  • 26 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Thermo Fisher Scientific logo
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $574.76
Low: $560.16
High: $580.45

50 Day Range

MA: $557.53
Low: $461.95
High: $597.56

52 Week Range

Now: $574.76
Low: $385.46
High: $610.97

Volume

1,961,632 shs

Average Volume

1,551,460 shs

Market Capitalization

$215.94 billion

P/E Ratio

33.20

Dividend Yield

0.30%

Beta

0.9

Frequently Asked Questions

What sell-side analysts currently cover shares of Thermo Fisher Scientific?

The following Wall Street analysts have issued stock ratings on Thermo Fisher Scientific in the last year: Argus, Bank of America Corporation, Barclays PLC, Citigroup Inc., Cowen Inc, Deutsche Bank Aktiengesellschaft, Evercore ISI, Hsbc Global Res, HSBC Holdings plc, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Raymond James Financial, Inc., Redburn Partners, Robert W. Baird, Royal Bank Of Canada, Sanford C. Bernstein, Scotiabank, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, Wall Street Zen, Weiss Ratings, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for TMO.

What is the current price target for Thermo Fisher Scientific?

0 Wall Street analysts have set twelve-month price targets for Thermo Fisher Scientific in the last year. Their average twelve-month price target is $602.35, suggesting a possible upside of 4.8%. Morgan Stanley has the highest price target set, predicting TMO will reach $670.00 in the next twelve months. HSBC Holdings plc has the lowest price target set, forecasting a price of $510.00 for Thermo Fisher Scientific in the next year.
View the latest price targets for TMO.

What is the current consensus analyst rating for Thermo Fisher Scientific?

Thermo Fisher Scientific currently has 4 hold ratings, 19 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TMO.

What other companies compete with Thermo Fisher Scientific?

Other companies that are similar to Thermo Fisher Scientific include Medpace, Agilent Technologies, AMN Healthcare Services, Danaher and Haemonetics. Learn More about companies similar to Thermo Fisher Scientific.

How do I contact Thermo Fisher Scientific's investor relations team?

Thermo Fisher Scientific's physical mailing address is 168 Third Avenue, Waltham MA, 02451. The medical research company's listed phone number is (781) 622-1000 and its investor relations email address is [email protected]. The official website for Thermo Fisher Scientific is www.thermofisher.com. Learn More about contacing Thermo Fisher Scientific investor relations.